Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...

AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

As National Diabetes Month gets underway, StrideMD is among the diabetes care providers, tech developers and drugmakers ...

PhRMA is pushing to get pharmacy benefit manager (PBM) reform over the line in Congress’ lame-duck session, using its first ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

Four months after calling for the resignation of four board members from Assertio Holdings, New York investment advisory firm ...

Havas Health has appointed Anna Maria Marra CEO of Europe. Marra is joining the healthcare agency after a 22-year run at ...